Reactions Weekly

, Volume 1748, Issue 1, pp 8–8 | Cite as

Immune checkpoint inhibitor toxicites from FAERS and OoSRs

Clinical study


  1. Raschi E, et al. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Targeted Oncology : 29 Mar 2019. Available from: URL:

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations